Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00856050 · OUTCOME

Progression Free Survival Rate at 12 Weeks

Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma · Source last updated 2017-04-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
90% Confidence Interval
Time frame
12 weeks

What was measured

Data below are reported as progression free rate (%).

Analysis population: 27 patients were enrolled, and 26 patients received at least one dose of study medication and were included in the analysis.

Groups in this outcome

Letrozole

letrozole 2.5mg by mouth per day

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Letrozole26

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Letrozole46Not reported2964Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        29
        upper Limit
        64
        value
        46
denoms
  1. counts
    1. group Id
      OG000
      value
      26
    units
    Participants
description
Data below are reported as progression free rate (%).
dispersion Type
90% Confidence Interval
groups
  1. description
    letrozole 2.5mg by mouth per day
    id
    OG000
    title
    Letrozole
param Type
NUMBER
population Description
27 patients were enrolled, and 26 patients received at least one dose of study medication and were included in the analysis.
reporting Status
POSTED
time Frame
12 weeks
title
Progression Free Survival Rate at 12 Weeks
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice